Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications

RNA

Volumn 13, Issue 10, 2007, Pages 1609-1624

  Aartsma Rus, Annemieke ^a   Van Ommen, Gert Jan B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antisense oligonucleotides; Duchenne muscular dystrophy; Exon skipping; Splicing; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; DYSTROPHIN; PHOSPHOROTHIOIC ACID DERIVATIVE;

BECKER MUSCULAR DYSTROPHY; DISEASE SEVERITY; DMD GENE; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE; GENE DISRUPTION; GENE FUNCTION; GENE MUTATION; HUMAN; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA SPLICING;

ANIMALS; EXONS; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; RNA SPLICE SITES; RNA SPLICING;

EID: 34748906143     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.653607     Document Type: Review

References (138)

1. Aartsma-Rus, A. and van Deutekom, J.C.T. 2007. Antisense-mediated reading-frame restoration as a genetic therapy for Duchenne muscular dystrophy. In Antisense elements (genetics) (ed. A.G. Hernandes). Novapublishers, Hauppauge, NY.
2. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., Bremmer-Bout, M., den Dunnen, J.T., Baas, F., van Ommen, G.J., and van Deutekom, J.C. 2003. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12: 907-914.
3. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., Bremmer-Bout, M., van Ommen, G.J., den Dunnen, J.T., and van Deutekom, J.C. 2004a. Antisense-induced multiexon skipping for duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet. 74: 83-92.
4. Aartsma-Rus, A., Kaman, W.E., Bremmer-Bout, M., Janson, A., Den Dunnen, J., van Ommen, G.J., and van Deutekom, J.C. 2004b. Comparative analysis of antisense oligonucleotide analogs for tageted DMD exon 46 skipping in muscle cells. Gene Ther. 11: 1391-1398.
5. Aartsma-Rus, A., Winter, C.L., Janson, A.A.M., Kaman, W.E., van Ommen, G.J., den Dunnen, J.T., and van Deutekom, J.C. 2005. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: Indication for steric hindrance of SR protein binding sites. Oligonucleotides 15: 284-297.
6. Aartsma-Rus, A., Janson, A.A., Heemskerk, J.A., De Winter, C.L., van Ommen, G.J., and van Deutekom, J.C. 2006a. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides. Ann. N. Y. Acad. Sci. 1082: 74-76.
7. Aartsma-Rus, A., Kaman, W.E., Weij, R., den Dunnen, J.T., van Ommen, G.J., and van Deutekom, J.C. 2006b. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol. Ther. 14: 401-407.
8. Aartsma-Rus, A., van Deutekom, J.C., Fokkema, I.F., van Ommen, G.J., and den Dunnen, J.T. 2006c. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34: 135-144.
9. Aartsma-Rus, A., Janson, A.A., van Ommen, G.-J.B., and van Deutekom, J.C.T. 2007. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med. Genet. 8: 43. doi: 10.1186/1471-2350-8-43.
10. Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S.D., Partridge, T.A., and Lu, Q.L. 2006. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12: 175-177.
11. Amantana, A. and Iversen, P.L. 2005. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr. Opin. Pharmacol. 5: 550-555.
12. Ars, E., Serra, E., Garcia, J., Kruyer, H., Gaona, A., Lazaro, C., and Estivill, X. 2000. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum. Mol. Genet. 9: 237-247.
13. Asparuhova, M.B., Marti, G., Liu, S., Serhan, F., Trono, D., and Schumperli, D. 2007. Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J. Gene Med. 9: 323-334.
14. Beggs, A.H., Koenig, M., Boyce, F.M., and Kunkel, L.M. 1990. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum. Genet. 86: 45-48.
15. Beroud, C., Tuffery-Giraud, S., Matsuo, M., Hamroun, D., Humbertclaude, V., Monnier, N., Moizard, M.P., Voelckel, M.A., Calemard, L.M., Boisseau, P., et al. 2007. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum. Mutat. 28: 196-202.
16. Blankinship, M.J., Gregorevic, P., Allen, J.M., Harper, S.Q., Harper, H., Halbert, C.L., Miller, D.A., and Chamberlain, J.S. 2004. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther. 10: 671-678.
17. Bond, U.M., Yario, T.A., and Steitz, J.A. 1991. Multiple processing-defective mutations in a mammalian histone pre-mRNA are suppressed by compensatory changes in U7 RNA both in vivo and in vitro. Genes & Dev. 5: 1709-1722.
18. Burns, K., Martinon, F., Esslinger, C., Pahl, H., Schneider, P., Bodmer, J.L., Di Marco, F., French, L., and Tschopp, J. 1998. MyD88, an adapter protein involved in interleukin-1 signaling. J. Biol. Chem. 273: 12203-12209.
19. Burns, K., Janssens, S., Brissoni, B., Olivos, N., Beyaert, R., and Tschopp, J. 2003. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197: 263-268.
20. Cartegni, L. and Krainer, A.R. 2002. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 30: 377-384.
21. Cartegni, L. and Krainer, A.R. 2003. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol. 10: 120-125.
22. Cartegni, L., Chew, S.L., and Krainer, A.R. 2002. Listening to silence and understanding nonsense: Exonic mutations that affect splicing. Nat. Rev. Genet. 3: 285-298.
23. Cartegni, L., Wang, J., Zhu, Z., Zhang, M.Q., and Krainer, A.R. 2003. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 31: 3568-3571. doi: 10.1093/nar/gkg616.
24. Chester, A., Scott, J., Anant, S., and Navaratnam, N. 2000. RNA editing: Cytidine to uridine conversion in apolipoprotein B mRNA. Biochim. Biophys. Acta 1494: 1-13.
25. Davis, M.I., Bennett, M.J., Thomas, L.M., and Bjorkman, P.J. 2005. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. 102: 5981-5986.
26. Deburgrave, N., Daoud, F., Llense, S., Barbot, J.C., Récan, D., Peccate, C., Burghes, A.H., Béroud, C., Garcia, L., Kaplan, J.C., et al. 2007. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum. Mutat. 28: 183-195.
27. Disset, A., Bourgeois, C.F., Benmalek, N., Claustres, M., Stevenin, J., and Tuffery-Giraud, S. 2006. An exon skipping-associated non-sense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum. Mol. Genet. 15: 999-1013.
28. Dominski, Z. and Kole, R. 1993. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. 90: 8673-8677.
29. Dunckley, M.G., Manoharan, M., Villiet, P., Eperon, I.C., and Dickson, G. 1998. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet. 7: 1083-1090.
30. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
31. Emery, A.E. 2002. The muscular dystrophies. Lancet 359: 687-695.
32. England, S.B., Nicholson, L.V., Johnson, M.A., Forrest, S.M., Love, D.R., Zubrzycka-Gaarn, E.E., Bulman, D.E., Harris, J.B., and Davies, K.E. 1990. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343: 180-182.
33. Fairbrother, W.G., Yeh, R.F., Sharp, P.A., and Burge, C.B. 2002. Predictive identification of exonic splicing enhancers in human genes. Science 297: 1007-1013.
34. Fairbrother, W.G., Holste, D., Burge, C.B., and Sharp, P.A. 2004. Single nucleotide polymorphism-based validation of exonic splicing enhancers. PLoS Biol. 2: e268. doi: 10.1371/journal.pbio.0020268.
35. Fall, A.M., Johnsen, R., Honeyman, K., Iversen, P., Fletcher, S., and Wilton, S.D. 2006. Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet. Vaccines Ther. 4: 3. doi: 10.1186/1479-0556-4-3.
36. Fine, J.D., Eady, R.A., Bauer, E.A., Briggaman, R.A., Bruckner-Tuderman, L., Christiano, A., Heagerty, A., Hintner, H., Jonkman, M.F., McGrath, J., et al. 2000. Revised classification system for inherited epidermolysis bullosa: Report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J. Am. Acad. Dermatol. 42: 1051-1066.
37. Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D., and Wilton, S.D. 2006. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med. 8: 207-216.
38. Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D., Steinhaus, J.P., Moulton, H.M., Iversen, P.L., and Wilton, S.D. 2007. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther. doi: 10.1038/sj.mt.6300245.
39. Fluiter, K., ten Asbroek, A.L., de Wissel, M.B., Jakobs, M.E., Wissenbach, M., Olsson, H., Olsen, O., Oerum, H., and Baas, F. 2003. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucl. Acids Res. 31: 953-962. doi: 10.1093/nar/gkg185.
40. Freiburg, A., Trombitas, K., Hell, W., Cazorla, O., Fougerousse, F., Centner, T., Kolmerer, B., Witt, C., Beckmann, J.S., Gregorio, C.C., et al. 2000. Series of exon-skipping events in the elastic spring region of titin as the structural basis for myofibrillar elastic diversity. Circ. Res. 86: 1114-1121.
41. Friedman, K.J., Kole, J., Cohn, J.A., Knowles, M.R., Silverman, L.M., and Kole, R. 1999. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274: 36193-36199.
42. Gebski, B.L., Mann, C.J., Fletcher, S., and Wilton, S.D. 2003. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 12: 1801-1811.
43. Ghosh, D. and Barry, M.A. 2005. Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J. Virol. 79: 13667-13672.
44. Ginjaar, I.B., Kneppers, A.L., v d Meulen, J.D., Anderson, L.V., Bremmer-Bout, M., van Deutekom, J.C., Weegenaar, J., den Dunnen, J.T., and Bakker, E. 2000. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family. Eur. J. Hum. Genet. 8: 793-796.
45. Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., and Crowther, R.A. 1989. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3: 519-526.
46. Goto, M., Sawamura, D., Nishie, W., Sakai, K., McMillan, J.R., Akiyama, M., and Shimizu, H. 2006. Targeted skipping of a single exon harboring a premature termination codon mutation: Implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J. Invest. Dermatol. 126: 2614-2620.
47. Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.C., Garcia, L., and Danos, O. 2004. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306: 1796-1799.
48. Harding, P.L., Fall, A.M., Honeyman, K., Fletcher, S., and Wilton, S.D. 2007. The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol. Ther. 15: 157-166.
49. Hausen, P. and Stein, H. 1970. Ribonuclease H - An enzyme degrading the RNA moiety of DNA-RNA hybrids. Eur. J. Biochem. 14: 278-283.
50. Hoffman, E.P., Brown Jr., R.H., and Kunkel, L.M. 1987. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
51. Hoffman, E.P., Fischbeck, K.H., Brown, R.H., Johnson, M., Medori, R., Loike, J.D., Harris, J.B., Waterston, R., Brooke, M., Specht, L., et al. 1988. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N. Engl. J. Med. 318: 1363-1368.
52. Hua, Y., Vickers, T.A., Baker, B.F., Bennett, C.F., and Krainer, A.R. 2007. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 5: e73. doi: 10.1371/journal.pbio. 0050073.
53. Jablonka, S., Rossoll, W., Schrank, B., and Sendtner, M. 2000. The role of SMN in spinal muscular atrophy. J. Neurol. 247: 37-42.
54. Kalbfuss, B., Mabon, S.A., and Misteli, T. 2001. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J. Biol. Chem. 276: 42986-42993.
55. Karras, J.G., McKay, R.A., Dean, N.M., and Monia, B.P. 2000. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-α chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol. Pharmacol. 58: 380-387.
56. Karras, J.G., Maier, M.A., Lu, T., Watt, A., and Manoharan, M. 2001. Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-alpha chain. Biochemistry 40: 7853-7859.
57. Khoo, B., Roca, X., Chew, S.L., and Krainer, A.R. 2007. Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Mol. Biol. 8: 3. doi: 10.1186/1471-2199-8-3.
58. Koenig, M., Monaco, A.P., and Kunkel, L.M. 1988. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53: 219-226.
59. Kole, R. and Sazani, P. 2001. Antisense effects in the cell nucleus: Modification of splicing. Curr. Opin. Mol. Ther. 3: 229-234.
60. Kolonin, M.G., Sun, J., Do, K.A., Vidal, C.I., Ji, Y., Baggerly, K.A., Pasqualini, R., and Arap, W. 2006. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J. 20: 979-981.
61. Krawczak, M., Reiss, J., and Cooper, D.N. 1992. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences. Hum. Genet. 90: 41-54.
62. Kurreck, J. 2003. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270: 1628-1644.
63. Lewis, B.P., Green, R.E., and Brenner, S.E. 2003. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc. Natl. Acad. Sci. 100: 189-192.
64. Liechti-Gallati, S., Koenig, M., Kunkel, L.M., Frey, D., Boltshauser, E., Schneider, V., Braga, S., and Moser, H. 1989. Molecular deletion patterns in Duchenne and Becker type muscular dystrophy. Hum. Genet. 81: 343-348.
65. Liu, S., Asparuhova, M., Brondani, V., Ziekau, I., Klimkait, T., and Schumperli, D. 2004. Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res. 32: 3752-3759. doi: 10.1093/nar/gkh715.
66. Lu, Q.L., Mann, C.J., Lou, F., Bou-Gharios, G., Morris, G.E., Xue, S.A., Fletcher, S., Partridge, T.A., and Wilton, S.D. 2003. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 8: 1009-1014.
67. Mann, C.J., Honeyman, K., Cheng, A.J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J.E., Partridge, T.A., and Wilton, S.D. 2001. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. 98: 42-47.
68. Mann, C.J., Honeyman, K., McClorey, G., Fletcher, S., and Wilton, S.D. 2002. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med. 4: 644-654.
69. Marquis, J., Meyer, K., Angehrn, L., Kampfer, S.S., Rothen-Rutishauser, B., and Schumperli, D. 2007. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol. Ther. doi: 10.1038/sj.mt.6300200.
70. Marwick, C. 1998. First "antisense" drug will treat CMV retinitis. JAMA 280: 871.
71. Matsumura, K. and Campbell, K.P. 1994. Dystrophin-glycoprotein complex: Its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve 17: 2-15.
72. Matsuo, M., Masumura, T., Nakajima, T., Kitoh, Y., Takumi, T., Nishio, H., Koga, J., and Nakamura, H. 1990. A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene. Biochem. Biophys. Res. Commun. 170: 963-967.
73. Matsuo, M., Masumura, T., Nishio, H., Nakajima, T., Kitoh, Y., Takumi, T., Koga, J., and Nakamura, H. 1991. Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe. J. Clin. Invest. 87: 2127-2131.
74. McClorey, G., Fall, A.M., Moulton, H.M., Iversen, P.L., Rasko, J.E., Ryan, M., Fletcher, S., and Wilton, S.D. 2006a. Induced dystrophin exon skipping in human muscle explants. Neuromuscul. Disord. 16: 583-590.
75. McClorey, G., Moulton, H.M., Iversen, P.L., Fletcher, S., and Wilton, S.D. 2006b. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 13: 1373-1381.
76. McGrath, J.A., Ashton, G.H., Mellerio, J.E., Salas-Alanis, J.C., Swensson, O., McMillan, J.R., and Eady, R.A. 1999. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing nonsense or frameshift mutations. J. Invest. Dermatol. 113: 314-321.
77. Mercatante, D.R., Sazani, P., and Kole, R. 2001. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. Curr. Cancer Drug Targets 1: 211-230.
78. Mercatante, D.R., Mohler, J.L., and Kole, R. 2002. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem. 277: 49374-49382.
79. Mirabella, M., Galluzzi, G., Manfredi, G., Bertini, E., Ricci, E., De Leo, R., Tonali, P., and Servidei, S. 1998. Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy. Neurology 51: 592-595.
80. Monaco, A.P., Bertelson, C.J., Liechti-Gallati, S., Moser, H., and Kunkel, L.M. 1988. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2: 90-95.
81. Morita, K., Hasegawa, C., Kaneko, M., Tsutsumi, S., Sone, J., Ishikawa, T., Imanishi, T., and Koizumi, M. 2002. 2′-O,4′-C- ethylene-bridged nucleic acids (ENA): Highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg. Med. Chem. Lett. 12: 73-76.
82. Morita, K., Takagi, M., Hasegawa, C., Kaneko, M., Tsutsumi, S., Sone, J., Ishikawa, T., Imanishi, T., and Koizumi, M. 2003. Synthesis and properties of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides. Bioorg. Med. Chem. 11: 2211-2226.
83. Munsat, T.L. and Davies, K.E. 1992. International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul. Disord. 2: 423-428.
84. Muntoni, F., Bushby, K., and van Ommen, G.-J.B. 2005. 128th ENMC international workshop on "Preclinical optimization and Phase I/II clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy" 22-24 October 2004, Naarden, The Netherlands. Neuromuscul. Disord. 15: 450-457.
85. O'Byrne, P.M. 2006. Cytokines or their antagonists for the treatment of asthma. Chest 130: 244-250.
86. O'Keefe, D.S., Bacich, D.J., and Heston, W.D. 2004. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 58: 200-210.
87. Obika, S., Nanbu, D., Hari, Y., Andon, J.L., Moria, K.I., Doi, T., and Imanishi, T. 1998. Stability and structural features of the duplexes containing nucleoside analogues with fixed N-type conformation, 2′-O,4′- C-methyleneribonucleosides. Tetrahedron Lett. 39: 5401-5404.
88. Panayi, G.S., Corrigall, V.M., and Pitzalis, C. 2001. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum. Dis. Clin. North Am. 27: 317-334.
89. Pramono, Z.A., Takeshima, Y., Alimsardjono, H., Ishii, A., Takeda, S., and Matsuo, M. 1996. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem. Biophys. Res. Commun. 226: 445-449.
90. Reddy, J.C. and Licht, J.D. 1996. The WT1 Wilms' tumor suppressor gene: How much do we really know? Biochim. Biophys. Acta 1287: 1-28.
91. Renshaw, J., Orr, R.M., Walton, M.I., Te, P.R., Williams, R.D., Wancewicz, E.V., Monia, B.P., Workman, P., and Pritchard-Jones, K. 2004. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense downregulation of exon 5 alters target gene expression and inhibits cell survival. Mol. Cancer Ther. 3: 1467-1484.
92. Robberson, B.L., Cote, G.J., and Berget, S.M. 1990. Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol. Cell. Biol. 10: 84-94.
93. Roberts, R.G., Coffey, A.J., Bobrow, M., and Bentley, D.R. 1993. Exon structure of the human dystrophin gene. Genomics 16: 536-538.
94. Roberts, R.G., Gardner, R.J., and Bobrow, M. 1994. Searching for the 1 in 2,400,000: A review of dystrophin gene point mutations. Hum. Mutat. 4: 1-11.
95. Roberts, J., Palma, E., Sazani, P., Orum, H., Cho, M., and Kole, R. 2006. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol. Ther. 14: 471-475.
96. Samoylova, T.I. and Smith, B.F. 1999. Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve 22: 460-466.
97. Sazani, P., Gemignani, F., Kang, S.H., Maier, M.A., Manoharan, M., Persmark, M., Bortner, D., and Kole, R. 2002. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20: 1228-1233.
98. Scaffidi, P. and Misteli, T. 2005. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat. Med. 11: 440-445.
99. Scharnhorst, V., van der Eb, A.J., and Jochemsen, A.G. 2001. WT1 proteins: Functions in growth and differentiation. Gene 273: 141-161.
100. Schwarze, U., Starman, B.J., and Byers, P.H. 1999. Redefinition of exon 7 in the COL1A1 gene of type I collagen by an intron 8 splice-donor-site mutation in a form of osteogenesis imperfecta: Influence of intron splice order on outcome of splice-site mutation. Am. J. Hum. Genet. 65: 336-344.
101. Seeley, M., Huang, W., Chen, Z., Wolff, W.O., Lin, X., and Xu, X. 2007. Depletion of zebrafish titin reduces cardiac contractility by disrupting the assembly of Z-discs and A-bands. Circ. Res. 100: 238-245.
102. Shiga, N., Takeshima, Y., Sakamoto, H., Inoue, K., Yokota, Y., Yokoyama, M., and Matsuo, M. 1997. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J. Clin. Invest. 100: 2204-2210.
103. Sicinski, P., Geng, Y., Ryder-Cook, A.S., Barnard, E.A., Darlison, M.G., and Barnard, P.J. 1989. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244: 1578-1580.
104. Sierakowska, H., Sambade, M.J., Agrawal, S., and Kole, R. 1996. Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. 93: 12840-12844.
105. Skordis, L.A., Dunckley, M.G., Yue, B., Eperon, I.C., and Muntoni, F. 2003. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl. Acad. Sci. 100: 4114-4119.
106. Smith, P.J., Zhang, C., Wang, J., Chew, S.L., Zhang, M.Q., and Krainer, A.R. 2006. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum. Mol. Genet. 15: 2490-2508.
107. Soutar, A.K. and Naoumova, R.P. 2007. Mechanisms of disease: Genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4: 214-225.
108. Spillantini, M.G. and Goedert, M. 1998. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21: 428-433.
109. Srebrow, A. and Kornblihtt, A.R. 2006. The connection between splicing and cancer. J. Cell Sci. 119: 2635-2641.
110. Stojdl, D.F. and Bell, J.C. 1999. SR protein kinases: The splice of life. Biochem. Cell Biol. 77: 293-298.
111. Su, S.L., Huang, I.P., Fair, W.R., Powell, C.T., and Heston, W.D. 1995. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res. 55: 1441-1443.
112. Summerton, J. and Weller, D. 1997. Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7: 187-195.
113. Surono, A., Van Khanh, T., Takeshima, Y., Wada, H., Yagi, M., Takagi, M., Koizumi, M., and Matsuo, M. 2004. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Hum. Gene Ther. 15: 749-757.
114. Suter, D., Tomasini, R., Reber, U., Gorman, L., Kole, R., and Schumperli, D. 1999. Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations. Hum. Mol. Genet. 8: 2415-2423.
115. Tacke, R. and Manley, J.L. 1995. The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities. EMBO J. 14: 3540-3551.
116. Takeshima, Y., Nishio, H., Sakamoto, H., Nakamura, H., and Matsuo, M. 1995. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J. Clin. Invest. 95: 515-520.
117. Takeshima, Y., Wada, H., Yagi, M., Ishikawa, Y., Minami, R., Nakamura, H., and Matsuo, M. 2001. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev. 23: 788-790.
118. Takeshima, Y., Yagi, M., Wada, H., Ishibashi, K., Nishiyama, A., Kakumoto, M., Sakaeda, T., Saura, R., Okumura, K., and Matsuo, M. 2006. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr. Res. 59: 690-694.
119. Tennyson, C.N., Klamut, H.J., and Worton, R.G. 1995. The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. Nat. Genet. 9: 184-190.
120. Teraoka, S.N., Telatar, M., Becker-Catania, S., Liang, T., Onengut, S., Tolun, A., Chessa, L., Sanal, O., Bernatowska, E., Gatti, R.A., et al. 1999. Splicing defects in the ataxia-telangiectasia gene, ATM: Underlying mutations and consequences. Am. J. Hum. Genet. 64: 1617-1631.
121. Tuffery-Giraud, S., Saquet, C., Chambert, S., Echenne, B., Marie, C.J., Rivier, F., Cossee, M., Philippe, C., Monnier, N., Bieth, E., et al. 2004. The role of muscle biopsy in analysis of the dystrophin gene in Duchenne muscular dystrophy: Experience of a national referral center. Neuromuscul. Disord. 14: 650-658.
122. Uitto, J., Hovnanian, A., and Christiano, A.M. 1995. Premature termination codon mutations in the type VII collagen gene (COL7A1) underlie severe recessive dystrophic epidermolysis bullosa. Proc. Assoc. Am. Physicians 107: 245-252.
123. van Deutekom, J.C. and van Ommen, G.J. 2003. Advances in Duchenne muscular dystrophy gene therapy. Nat. Rev. Genet. 4: 774-783.
124. van Deutekom, J.C., Bremmer-Bout, M., Janson, A.A., Ginjaar, I.B., Baas, F., den Dunnen, J.T., and van Ommen, G.J. 2001. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10: 1547-1554.
125. Varani, L., Hasegawa, M., Spillantini, M.G., Smith, M.J., Murrell, J.R., Ghetti, B., Klug, A., Goedert, M., and Varani, G. 1999. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc. Natl. Acad. Sci. 96: 8229-8234.
126. Vickers, T.A., Zhang, H., Graham, M.J., Lemonidis, K.M., Zhao, C., and Dean, N.M. 2006. Modification of MyD88 mRNA splicing and inhibition of IL-1β signaling in cell culture and in mice with a 2′-O- methoxyethyl-modified oligonucleotide. J. Immunol. 176: 3652-3661.
127. Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hokfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., et al. 2000. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. 97: 5633-5638.
128. White, S.J., Aartsma-Rus, A., Flanigan, K.M., Weiss, R.B., Kneppers, A.L., Lalic, T., Janson, A.A., Ginjaar, H.B., Breuning, M.H., and den Dunnen, J.T. 2006. Duplications in the DMD gene. Hum. Mutat. 27: 938-945.
129. Whitfield, A.J., Barrett, P.H., van Bockxmeer, F.M., and Burnett, J.R. 2004. Lipid disorders and mutations in the APOB gene. Clin. Chem. 50: 1725-1732.
130. Williams, T. and Kole, R. 2006. Analysis of prostate-specific membrane antigen splice variants in LNCap cells. Oligonucleotides 16: 186-195.
131. Wilton, S.D. and Fletcher, S. 2005. Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now? Neuromuscul. Disord. 15: 399-402.
132. Wilton, S.D., Lloyd, F., Carville, K., Fletcher, S., Honeyman, K., Agrawal, S., and Kole, R. 1999. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul. Disord. 9: 330-338.
133. Wilton, S.D., Fall, A.M., Harding, P.L., McClorey, G., Coleman, C., and Fletcher, S. 2007. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol. Ther. 15: 1288-1296.
134. Wimmer, K., Roca, X., Beiglbock, H., Callens, T., Etzler, J., Rao, A.R., Krainer, A.R., Fonatsch, C., and Messiaen, L. 2007. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice-site disruption. Hum. Mutat. 28: 599-612.
135. Wu, J.Y. and Maniatis, T. 1993. Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell 75: 1061-1070.
136. Zamecnik, P.C. and Stephenson, M.L. 1978. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. 75: 280-284.
137. Zhang, X.H. and Chasin, L.A. 2004. Computational definition of sequence motifs governing constitutive exon splicing. Genes & Dev. 18: 1241-1250.
138. Zuker, M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucl. Acids Res. 31: 3406-3415. doi: 10.1093/nar/gkg595.